Get started

Newhighs

$SCS To Keep Rallying After Q3 Beat$SCS made new 52-week highs after posting a strong Q3. Judging from the technical breakout, we believe this rally will continue. Steelcase (SCS +16.9%) Q3 revenue increased 6% Y/Y to $955M, led by strong growth in the Americas on favorable timing of shipments, in part due to the timing of the U.S. Thanksgiving holiday. Operating margin improves ~290bps to 7.9%, with gross margin up 220bps to 33.1% driven by pricing benefits, lower commodity costs, and higher absorption of fixed costs, partially offset by unfavorable business mix. Steelcase expects FY2020 diluted EPS between $1.41 to $1.45, including Q4 estimate of $0.30 to $0.34. Forecasts FY2020 revenue to be ~$3.7B and Q4 sales in the range of $905M to $930M. Steelcase Inc. manufactures and sells integrated furniture settings, user-centered technologies, and interior architectural products. It operates through Americas, EMEA, and Other Category segments. The company's furniture portfolio includes panel, fence and beam-based furniture systems, storage products, fixed and height-adjustable desks, benches, and tables, as well as complementary products, including worktools. Its seating products comprise ergonomic task chairs; seating for collaborative or casual settings; and specialty seating for specific vertical markets, such as healthcare and education. The company's interior architectural products include full and partial height walls and architectural pods. It also provides textiles, wall coverings, and surface imaging solutions for architects and designers; and ceramic steel surfaces for use in various applications, including static whiteboards and chalkboards through third party fabricators and distributors, as well as workplace strategy consulting, data-driven space measurement, lease origination, furniture and asset management, and hosted event services. The company markets and sells its products to corporate, government, healthcare, education, and retail customers under the Steelcase, Coalesse, Turnstone, Smith System, AMQ, Orangebox, Designtex, and PolyVision brands. It distributes its products and services through a network of independent and company-owned dealers, as well as directly to end-use customers. The company was founded in 1912 and is headquartered in Grand Rapids, Michigan. As always, use protective stops and trade with caution. Good luck to all!
NYSE:SCSLong
by InsiderFinancial
$CAI Set To Keep Climbing$CAI has broken out to the upside on the news that the keep is evaluating its strategic options. Yesterday's news headline: CAI International jumps (CAI +15.2%) as the company announces that it is exploring potential strategic alternatives to maximize stockholder value. CAI has appointed Centerview Partners as its strategic financial advisor. $CAI is trading at just 9x earnings and 0.86x book value. The stock still looks cheap. CAI International, Inc. operates as transportation finance and logistics company in the United States and internationally. The company operates through three segments: Container Leasing, Rail Leasing, and Logistics. It leases, re-leases, and disposes equipment; and contracts for the repair, repositioning, and storage of equipment. The company leases its container equipment to lessees under long-term, short-term, and finance leases. It also sells containers; and manages equipment for to third-party investors, as well as sells used containers. In addition, the company leases railcars consisting of box cars for paper and forest products; covered hoppers for grain, cement, sand, plastic pallets, and other industrial products; general purpose tank cars that are used to transport food-grade, and other liquid and gaseous commodities; gondolas for coal and steel; and general service flat cars. Further, it offers domestic and international logistics services, including intermodal, truck brokerage, port drayage, warehousing, international ocean freight, and freight forwarding, as well as the arrangement and coordination of international air freight services and customs brokerage; international export and import services for full container loads, less than container loads, perishable cargo, project cargo, and airfreight; and transportation management services and technology solutions, including shipment optimization, load consolidation, mode selection, carrier management, load planning and execution, and Web-based shipment visibility. As of December 31, 2018, the company had a container fleet comprised 1,568,707 cost equivalent units; and an owned fleet of 7,279 railcars in North America. The company was formerly known as Container Applications International, Inc. and changed its name to CAI International, Inc. in February 2007. CAI International, Inc. was founded in 1989 and is headquartered in San Francisco, California. As always, use protective stops and trade with caution. Good luck to all!
CLong
by InsiderFinancial
Major Breakout In $SGEN$SGEN has been on a long-term bull run as we look at the weekly chart. Positive topline results signal that the bull run is set to continue and we expect $SGEN to keep racking up new 52-week highs. Seattle Genetics (NASDAQ:SGEN) is up in reaction to positive results from a Phase 2 clinical trial, HER2CLIMB, evaluating combination of tucatinib, Roche's Herceptin (trastuzumab) and chemo agent capecitabine compared to trastuzumab and capecitabine alone in patients with locally advanced unresectable/metastatic HER2-positive breast cancer. The study met the primary endpoint of progression-free survival (PFS) at month 48 with 48% less risk of cancer progression or death (hazard ratio = 0.54). Key secondary endpoints of overall survival (OS) and PFS in patients with brain metastases were also met. On the safety front, the most common adverse events were diarrhea, palmar-plantar erythrodysaesthesia syndrome (redness, swelling and pain in the palms and/or soles of the feet), nausea, fatigue and vomiting. Serious/life-threatening adverse events included diarrhea (12.9% vs 8.6% in the comparator arm), increased AST (4.5% vs. 0.5%), increased ALT (5.4% vs. 0.5%) and increased bilirubin (0.7% vs. 2.5%). Increases in AST, ALT and bilirubin indicate liver stress/damage. Based on the successful results, the company intends to unblind the trial and offer tucatinib, a tyrosine kinase inhibitor, to patients in the comparator arm. It also plans to file a U.S. marketing application in Q1 2020. As always, trade with caution and use protective stops. Good luck to all!
SLong
by InsiderFinancial
$JACK Keep Climbing While $SPY Sells Off$JACK keeps looking more and more interesting. While it is hard to buy a stock that keeps making new highs, the recent price action tells us that someone is accumulating a position. We are seeing more green days than red days in $JACK. @Ivanoff tweeted today that something is brewing and we agree. We've been watching $JACK for some time and haven't pulled the trigger, but we are now. Jack in the Box Inc. operates and franchises Jack in the Box quick-service restaurants. As of March 19, 2019, it operated and franchised approximately 2,200 Jack in the Box restaurants in 21 states and Guam. The company was founded in 1951 and is headquartered in San Diego, California. As always, trade with caution and use protective stops. Good luck to all!
NASDAQ:JACKLong
by InsiderFinancial
$IDT IDT Corp A Buy Above $8.7$IDT has been one that we have traded well in the past. The stock has a history of explosive moves. Above $8.7 and we see the stock get going and we believe we will see $10 to $12 in rather short order. $IDT started climbing last week after reporting Q3 earnings. The highlight was the company in the quarter swung from a loss last year to being profitable. The company also reported double-digit revenue growth in its emerging segments. We believe new highs are coming sooner rather than later. As always, trade with caution and use protective stops. Good luck to all!
NYSE:IDTLong
by InsiderFinancial
1
Fib Level Finds Key Support for $BTC - $10K in SIGHT!The price dropped from the 9K highs to find support at the 61.8% Fibonacci retracement level around $7500. The directional index lines did cross but on falling momentum. This is a picture of a bearish correction in an overall bullish market, so the support on the price chart should hold and so far it has bounced. The RSI also dropped, but still remains well inside the bullish zone. The blue bullish trend line on the chart is our guide of support as we move higher and bring $10K back into our sights! The highlighted triangle is where price should trade int he coming weeks. Watch trend line support to hold and previous highs to be re-examined and then new highs to follow. $10K! Happy Trading! Fibo
COINBASE:BTCUSDLong
by FiboSwanny
1